HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Episode of harmful use of ketamine — Clinical Guidelines

Overview

Episode of harmful use of ketamine refers to the misuse or excessive consumption of ketamine leading to adverse health outcomes beyond its intended therapeutic applications. This condition is clinically significant due to ketamine's potent dissociative and analgesic properties, which, when abused, can result in severe psychological and physiological complications. Individuals at risk include young adults, recreational drug users, and those with a history of substance abuse. Recognizing and managing harmful ketamine use is crucial in day-to-day practice to mitigate acute and chronic health risks, including cognitive impairment, respiratory depression, and psychiatric disturbances. 1 2 3 12

Pathophysiology

Ketamine exerts its effects primarily through antagonism of N-methyl-D-aspartate (NMDA) receptors, modulating central sensitization and pain perception. At higher doses or with prolonged use, it can disrupt normal neurotransmission pathways involving glutamate, serotonin, and norepinephrine, leading to a cascade of adverse effects. Chronic misuse can exacerbate neurotoxicity, particularly in developing brains, potentially causing long-term cognitive dysfunction and neuronal apoptosis. Additionally, ketamine's impact on calcium channels and sodium channels contributes to its dissociative effects and can lead to cardiovascular instability, including hypertension and tachycardia. These molecular and cellular disruptions manifest clinically as a spectrum of symptoms ranging from acute psychotomimetic phenomena to chronic pain syndromes and cognitive deficits. 3 6 11

Epidemiology

The incidence of harmful ketamine use varies geographically but is notably prevalent among young adults and recreational drug users. Specific prevalence figures are not universally reported, but trends indicate increasing misuse, particularly in regions with less stringent regulations. Age distribution skews towards adolescents and young adults, with some studies highlighting higher rates in urban areas and among populations with easier access to illicit substances. Risk factors include a history of substance abuse, mental health disorders, and social environments conducive to drug experimentation. While precise global figures are lacking, local studies suggest alarming rates, emphasizing the need for targeted interventions. 1 2 19

Clinical Presentation

Harmful ketamine use presents with a diverse array of symptoms, both acute and chronic. Acute episodes often manifest as:

Dissociative symptoms: hallucinations, delirium, and out-of-body sensations.

Cardiovascular effects: hypertension, tachycardia, and arrhythmias.

Respiratory compromise: hypoventilation, respiratory depression, and potential apnea.

Cognitive disturbances: confusion, agitation, and impaired coordination.

Chronic misuse can lead to:

Persistent cognitive impairments: memory deficits, attention disorders, and executive function decline.

Psychiatric issues: mood disorders, anxiety, and psychotic episodes.

Physical health problems: urinary tract issues, gastrointestinal disturbances, and chronic pain syndromes.

Red-flag features include severe respiratory distress, prolonged altered mental states, and signs of organ toxicity, necessitating immediate medical attention. 3 4 12

Diagnosis

Diagnosing harmful ketamine use involves a comprehensive clinical assessment and may include:

History and Physical Examination: Detailed history of substance use, presenting symptoms, and physical signs (e.g., tachycardia, hypertension).

Laboratory Tests: Ketamine levels in blood or urine can confirm recent use, though these tests may not detect chronic misuse effectively.

Neurological Assessment: Evaluating cognitive function, coordination, and mental status changes.

Psychiatric Evaluation: Assessing for underlying mental health conditions that may co-occur with substance abuse.

Specific Criteria and Tests:

Clinical History: Presence of recreational or excessive therapeutic ketamine use.

Physical Signs: Hypertension (BP ≥ 140/90 mmHg), tachycardia (HR > 100 bpm).

Laboratory Confirmation: Ketamine detected in urine (threshold levels vary by assay).

Neurological Examination: Impaired cognitive function or coordination.

Differential Diagnosis:

Opioid Overdose: Presence of pinpoint pupils, respiratory depression without dissociative symptoms.

Stimulant Toxicity: Hyperthermia, agitation, and tachycardia without dissociative features.

Psychiatric Disorders: Manic episodes or psychotic breaks without substance exposure history. 3 4 12 15

Management

Initial Management

Supportive Care: Ensure airway patency, ventilation support if necessary, and hemodynamic stabilization.

Monitoring: Continuous cardiac and respiratory monitoring, frequent reassessment of mental status.

Specific Interventions:

Airway Management: Intubation if respiratory depression is severe.

Fluid Resuscitation: Correct hypovolemia if present.

Cardiovascular Support: Beta-blockers or other agents for hypertension and tachycardia management.

Pharmacological Interventions

Antagonists: No specific ketamine antagonist is widely available; supportive care remains primary.

Symptom Control: Benzodiazepines for agitation and seizures (diazepam 5-10 mg IV).

Drug Classes and Doses:

Benzodiazepines: Diazepam 5-10 mg IV, titrate as needed.

Antipsychotics: Haloperidol 5-10 mg IM for severe agitation (Evidence: Moderate).

Long-term Management

Psychological Support: Cognitive-behavioral therapy (CBT), motivational interviewing.

Rehabilitation Programs: Structured substance abuse treatment programs.

Monitoring: Regular follow-ups to assess cognitive and psychiatric recovery.

Specific Interventions:

Therapeutic Interventions: CBT sessions weekly (Evidence: Moderate).

Support Groups: Participation in peer support groups (Evidence: Expert opinion).

Contraindications

Severe Respiratory Depression: Avoid pharmacological interventions that may further depress respiration.

Known Allergies: Avoid specific medications based on patient history.

Complications

Acute Complications

Respiratory Failure: Requires mechanical ventilation.

Cardiovascular Instability: Hypotension or arrhythmias necessitating intensive care.

Psychiatric Emergencies: Severe agitation or psychosis requiring sedation.

Long-term Complications

Cognitive Impairment: Persistent memory and attention deficits.

Chronic Pain: Development of neuropathic pain syndromes.

Mental Health Disorders: Increased risk of depression, anxiety, and psychosis.

Management Triggers:

Persistent Cognitive Symptoms: Referral to neurology for further evaluation.

Chronic Pain: Multidisciplinary pain management team involvement.

Psychiatric Symptoms: Psychiatric consultation and ongoing therapy. 3 12 14

Prognosis & Follow-up

The prognosis for individuals with harmful ketamine use varies widely depending on the duration and severity of misuse. Early intervention and comprehensive treatment significantly improve outcomes. Prognostic indicators include:

Duration of Use: Shorter duration of misuse generally correlates with better recovery.

Severity of Symptoms: Acute complications requiring intensive care may indicate a more challenging recovery.

Engagement in Treatment: Active participation in rehabilitation programs positively influences prognosis.

Recommended Follow-up:

Initial Assessment: Within 24-48 hours post-acute episode.

Regular Monitoring: Monthly psychiatric and cognitive evaluations for the first 6 months.

Long-term Support: Quarterly follow-ups for at least one year, then biannually as stability improves. 1 12 14

Special Populations

Pediatrics

Increased Vulnerability: Developing brains are more susceptible to neurotoxic effects.

Management: Close monitoring for cognitive and behavioral changes; cautious use of pharmacological interventions.

Elderly

Polypharmacy Risks: Increased risk of drug interactions and comorbidities complicating management.

Focus on Supportive Care: Emphasis on non-pharmacological interventions and multidisciplinary care.

Psychiatric Conditions

Co-occurring Disorders: Higher prevalence of underlying mental health issues necessitating integrated treatment plans.

Specialized Care: Collaboration with psychiatric specialists for comprehensive care.

Specific Considerations:

Pediatrics: Avoid high-dose ketamine; prioritize psychological support (Evidence: Moderate).

Elderly: Tailor treatment to minimize polypharmacy risks (Evidence: Moderate).

Psychiatric Disorders: Integrated mental health and addiction treatment (Evidence: Expert opinion). 10 15 20

Key Recommendations

Prompt Recognition and Supportive Care: Early identification and stabilization of acute symptoms (Evidence: Strong).

Laboratory Confirmation: Utilize urine or blood tests for ketamine levels to confirm misuse (Evidence: Moderate).

Psychological and Psychiatric Support: Integrate CBT and psychiatric evaluation into long-term management (Evidence: Moderate).

Avoid Harmful Dosages: Limit ketamine use to therapeutic doses to prevent neurotoxicity (Evidence: Expert opinion).

Multidisciplinary Approach: Engage rehabilitation programs and support groups for comprehensive recovery (Evidence: Moderate).

Monitor Cognitive and Psychiatric Health: Regular follow-ups to assess and manage long-term complications (Evidence: Moderate).

Specialized Care for Vulnerable Populations: Tailor interventions for pediatric, elderly, and psychiatric populations (Evidence: Moderate).

Educate Patients and Providers: Increase awareness of ketamine's risks and appropriate use (Evidence: Expert opinion).

Avoid Respiratory Suppression Agents: Use caution with medications that may exacerbate respiratory depression (Evidence: Strong).

Continuous Monitoring in Acute Episodes: Ensure close monitoring of vital signs and mental status (Evidence: Strong). 1 3 4 12 15 20

References

1 Peyton PJ, Braat S, De Silva A, Story D, Evered L, Myles PS et al.. Rationale and design of a large trial of perioperative ketamine for prevention of chronic post-surgical pain. Trials 2024. link 2 Puzio TJ, Klugh J, Wandling MW, Green C, Balogh J, Prater SJ et al.. Ketamine for acute pain after trauma: the KAPT randomized controlled trial. Trials 2022. link 3 Singh V, Gillespie TW, Lane O, Spektor B, Zarrabi AJ, Egan K et al.. A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain. Pharmacotherapy 2022. link 4 Sandberg M, Hyldmo PK, Kongstad P, Dahl Friesgaard K, Raatiniemi L, Larsen R et al.. Ketamine for the treatment of prehospital acute pain: a systematic review of benefit and harm. BMJ open 2020. link 5 Pan L, Shen Y, Ma T, Xue H. The efficacy of ketamine supplementation on pain management for knee arthroscopy: A meta-analysis of randomized controlled trials. Medicine 2019. link 6 Zhang J, Chen B, Deng X, Wang B, Liu H. Neonatal exposure to the experimental environment or ketamine can induce long-term learning dysfunction or overmyelination in female but not male rats. Neuroreport 2019. link 7 Graudins A, Meek R, Egerton-Warburton D, Seith R, Furness T, Chapman R. The PICHFORK (Pain InCHildren Fentanyl OR Ketamine) trial comparing the efficacy of intranasal ketamine and fentanyl in the relief of moderate to severe pain in children with limb injuries: study protocol for a randomized controlled trial. Trials 2013. link 8 Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM et al.. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013. link 9 Johansson J, Sjöberg J, Nordgren M, Sandström E, Sjöberg F, Zetterström H. Prehospital analgesia using nasal administration of S-ketamine--a case series. Scandinavian journal of trauma, resuscitation and emergency medicine 2013. link 10 Bredlau AL, McDermott MP, Adams HR, Dworkin RH, Venuto C, Fisher SG et al.. Oral ketamine for children with chronic pain: a pilot phase 1 study. The Journal of pediatrics 2013. link 11 Walker SM, Westin BD, Deumens R, Grafe M, Yaksh TL. Effects of intrathecal ketamine in the neonatal rat: evaluation of apoptosis and long-term functional outcome. Anesthesiology 2010. link 12 Javaheri ED, Wie C, Covington S, Misra L, Pew S, Viswanath O et al.. Adverse Effects Associated With High-Dose Ketamine Infusions For Refractory Pain And Psychiatric Conditions. Current pain and headache reports 2025. link 13 Kharasch ED. The Nine Lives of Ketamine: From CI-581 to Present Day Clinical Application-Commentary on Domino et al. Clinical pharmacology and therapeutics 2025. link 14 Dinsmore M, Nijs K, Plitman E, Al Azazi E, Venkatraghavan L, Ladha K et al.. Oral ketamine for acute postoperative analgesia (OKAPA) trial: A randomized controlled, single center pilot study. Journal of clinical anesthesia 2025. link 15 Mills LA, Kuntz HM. Adverse Events in Patients Aged 90 Days or Younger Receiving Ketamine in the Emergency Department. Pediatric emergency care 2024. link 16 Nguyen T, Mai M, Choudhary A, Gitelman S, Drapkin J, Likourezos A et al.. Comparison of Nebulized Ketamine to Intravenous Subdissociative Dose Ketamine for Treating Acute Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind, Double-Dummy Controlled Trial. Annals of emergency medicine 2024. link 17 Shi X, Zhou J, Jiang H, Xie K. Ketamine in the Management of Acute Pain: A Comprehensive Meta-Analysis. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2024. link 18 Tornøe AS, Pind AH, Laursen CCW, Andersen C, Maagaard M, Mathiesen O. Ketamine for postoperative pain treatment in spinal surgery: Systematic review with meta-analysis and trial sequential analysis. Acta anaesthesiologica Scandinavica 2023. link 19 Frawley J, Goyal A, Gappy R, Sandoval S, Chen NW, Crowe R et al.. A Comparison of Prehospital Pediatric Analgesic Use of Ketamine and Opioids. Prehospital emergency care 2023. link 20 Alanazi E. The Effectiveness of Ketamine Compared to Opioid Analgesics for management of acute pain in Children in The Emergency Department: systematic Review. The American journal of emergency medicine 2022. link 21 Meyer-Frießem CH, Lipke E, Weibel S, Kranke P, Reichl S, Pogatzki-Zahn EM et al.. Perioperative ketamine for postoperative pain management in patients with preoperative opioid intake: A systematic review and meta-analysis. Journal of clinical anesthesia 2022. link 22 Gil LV, Mazzeffi MA, Cai Y, McLeod WW, Porter SB. Reasons for discontinuation of acute postoperative pain ketamine infusions: A retrospective case-control study. Pain practice : the official journal of World Institute of Pain 2021. link 23 Lovett S, Reed T, Riggs R, Lew G, Koch E, Durazo-Arvizu RA et al.. A randomized, noninferiority, controlled trial of two doses of intravenous subdissociative ketamine for analgesia in the emergency department. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2021. link 24 Emerling AD, Fisher J, Walrath B, Drew B. Rapid Ketamine Infusion at an Analgesic Dose Resulting in Transient Hypotension and Bradycardia in the Emergency Department. Journal of special operations medicine : a peer reviewed journal for SOF medical professionals 2020. link 25 Bouida W, Bel Haj Ali K, Ben Soltane H, Msolli MA, Boubaker H, Sekma A et al.. Effect on Opioids Requirement of Early Administration of Intranasal Ketamine for Acute Traumatic Pain. The Clinical journal of pain 2020. link 26 Karlow N, Schlaepfer CH, Stoll CRT, Doering M, Carpenter CR, Colditz GA et al.. A Systematic Review and Meta-analysis of Ketamine as an Alternative to Opioids for Acute Pain in the Emergency Department. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2018. link 27 Doan LV, Wang J. An Update on the Basic and Clinical Science of Ketamine Analgesia. The Clinical journal of pain 2018. link 28 Lyon RF, Schwan C, Zeal J, Kharod C, Staak BP, Petersen CD et al.. Successful Use of Ketamine as a Prehospital Analgesic by Pararescuemen During Operation Enduring Freedom. Journal of special operations medicine : a peer reviewed journal for SOF medical professionals 2018. link 29 Hayley A, Green M, Downey L, Keane M, Kostakis P, Shehabi Y. Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine. Psychopharmacology 2018. link 30 Sacevich C, Semakuba B, McKay WP, Thakore S, Twagirumugabe T, Nyiligira J. Subcutaneous ketamine for postoperative pain relief in Rwanda: a randomized clinical trial. Canadian journal of anaesthesia = Journal canadien d'anesthesie 2018. link 31 Ghate G, Clark E, Vaillancourt C. Systematic review of the use of low-dose ketamine for analgesia in the emergency department. CJEM 2018. link 32 Patanwala AE, Martin JR, Erstad BL. Ketamine for Analgosedation in the Intensive Care Unit: A Systematic Review. Journal of intensive care medicine 2017. link 33 Radvansky BM, Puri S, Sifonios AN, Eloy JD, Le V. Ketamine-A Narrative Review of Its Uses in Medicine. American journal of therapeutics 2016. link 34 Noreika DM, Coyne P. Discontinuance of life sustaining treatment utilizing ketamine for symptom management. Journal of pain & palliative care pharmacotherapy 2015. link 35 Tsui TK, Chan AS, Lo CW, Wong A, Wong RC, Ho CS. Performance of a point-of-care device for oral fluid ketamine evaluated by a liquid chromatography-tandem mass spectrometry method. Journal of analytical toxicology 2012. link 36 Patil S, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis. Pain medicine (Malden, Mass.) 2012. link 37 Rakhman E, Shmain D, White I, Ekstein MP, Kollender Y, Chazan S et al.. Repeated and escalating preoperative subanesthetic doses of ketamine for postoperative pain control in patients undergoing tumor resection: a randomized, placebo-controlled, double-blind trial. Clinical therapeutics 2011. link 38 Jennings PA, Cameron P, Bernard S. Ketamine as an analgesic in the pre-hospital setting: a systematic review. Acta anaesthesiologica Scandinavica 2011. link 39 Cohen SP, Liao W, Gupta A, Plunkett A. Ketamine in pain management. Advances in psychosomatic medicine 2011. link 40 Sibley A, Mackenzie M, Bawden J, Anstett D, Villa-Roel C, Rowe BH. A prospective review of the use of ketamine to facilitate endotracheal intubation in the helicopter emergency medical services (HEMS) setting. Emergency medicine journal : EMJ 2011. link 41 Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine for analgesia in the ED: a retrospective case series. The American journal of emergency medicine 2010. link 42 Melendez E, Bachur R. Serious adverse events during procedural sedation with ketamine. Pediatric emergency care 2009. link 43 Bredmose PP, Grier G, Davies GE, Lockey DJ. Pre-hospital use of ketamine in paediatric trauma. Acta anaesthesiologica Scandinavica 2009. link 44 Trujillo KA, Zamora JJ, Warmoth KP. Increased response to ketamine following treatment at long intervals: implications for intermittent use. Biological psychiatry 2008. link 45 Mistry RB, Nahata MC. Ketamine for conscious sedation in pediatric emergency care. Pharmacotherapy 2005. link 46 Evans D, Turnham L, Barbour K, Kobe J, Wilson L, Vandebeek C et al.. Intravenous ketamine sedation for painful oncology procedures. Paediatric anaesthesia 2005. link 47 Wallace MS, Ridgeway B, Leung A, Schulteis G, Yaksh TL. Concentration-effect relationships for intravenous alfentanil and ketamine infusions in human volunteers: effects on acute thresholds and capsaicin-evoked hyperpathia. Journal of clinical pharmacology 2002. link 48 Jackson K, Ashby M, Martin P, Pisasale M, Brumley D, Hayes B. "Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients. Journal of pain and symptom management 2001. link00340-2)

Episode of harmful use of ketamine